Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Nectin-4/CD137 (via BT7480) | Statement: [Bicycle Therapeutics, targets, Nectin-4/CD137 (via BT7480)]

Target entity: Nectin-4/CD137 (via BT7480)
Context triple: [Bicycle Therapeutics, targets, Nectin-4/CD137 (via BT7480)]

• A. PD-1
  PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
• B. CD20 protein
  CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
• C. CD21
  CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
• D. BCMA
  BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
• E. programmed cell death protein 1
  Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor on T cells that downregulates immune responses and promotes self-tolerance, making it a key target in cancer immunotherapy.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: Nectin-4/CD137 (via BT7480)
Triple: [Bicycle Therapeutics, targets, Nectin-4/CD137 (via BT7480)]

Nectin-4/CD137 (via BT7480) refers to the tumor-targeted immune agonist mechanism of BT7480, a Bicycle Therapeutics drug candidate designed to engage Nectin-4–expressing cancer cells while activating the CD137 costimulatory receptor to stimulate anti-tumor immune responses.

Target entity: Nectin-4/CD137 (via BT7480)
Target entity description: Nectin-4/CD137 (via BT7480) refers to the tumor-targeted immune agonist mechanism of BT7480, a Bicycle Therapeutics drug candidate designed to engage Nectin-4–expressing cancer cells while activating the CD137 costimulatory receptor to stimulate anti-tumor immune responses.

• A. PD-1
  PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
• B. CD20 protein
  CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
• C. CD21
  CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
• D. BCMA
  BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
• E. programmed cell death protein 1
  Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor on T cells that downregulates immune responses and promotes self-tolerance, making it a key target in cancer immunotherapy.
• F. None of above. chosen